Catapult Therapeutics awarded EUR 3 million innovation credit from the Dutch government

Lelystad, The Netherlands, November 2016 – Catapult Therapeutics B.V., a preclinical-stage biopharmaceutical company developing cancer treatments, announced today that it has received an innovation credit of up to EUR 3 million from Rijksdienst voor Ondernemend Nederland, a division of the Dutch Ministry of Economic Affairs, to support the preclinical development of Catapult’s first-in-class anti-CCR7 antibody CAP-100.

Catapult is currently conducting the preclinical development of CAP-100, with an initial focus on treating B-cell malignancies. This is an important development because no curative treatment exists for B-cell cancer.

Dr Wim Mol, CEO of Catapult Therapeutics, said: “We are delighted to receive this funding to develop CAP-100. Innovation credit is only awarded to innovative projects with strong commercial prospects. The grant allows us to accelerate the preclinical development of our novel blood cancer treatment, which is medically very important for patients.”